<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>cardiovascular risk reduction &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/cardiovascular-risk-reduction/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 06 Sep 2025 12:47:45 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>cardiovascular risk reduction &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Study Shows Intensive Blood Pressure Targets Offer Cost-Effective Benefits</title>
		<link>https://bioengineer.org/study-shows-intensive-blood-pressure-targets-offer-cost-effective-benefits/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 19 Aug 2025 02:46:41 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[cardiovascular risk reduction]]></category>
		<category><![CDATA[Clinical Simulation Studies]]></category>
		<category><![CDATA[Cost-Effectiveness in Hypertension]]></category>
		<category><![CDATA[Hypertension Treatment Guidelines]]></category>
		<category><![CDATA[Intensive Blood Pressure Control]]></category>
		<guid isPermaLink="false">https://bioengineer.org/study-shows-intensive-blood-pressure-targets-offer-cost-effective-benefits/</guid>

					<description><![CDATA[A groundbreaking simulation study conducted by researchers affiliated with Mass General Brigham presents compelling evidence favoring more aggressive blood pressure control in patients at high cardiovascular risk. The results, freshly published in the prestigious Annals of Internal Medicine, challenge conventional hesitations surrounding overtreatment in hypertension management. Utilizing rigorous data-driven methods, this research underscores the net [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">256270</post-id>	</item>
		<item>
		<title>Empowering Patients with Continuous Care to Sustain Weight Loss</title>
		<link>https://bioengineer.org/empowering-patients-with-continuous-care-to-sustain-weight-loss/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 27 May 2025 15:40:23 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[cardiovascular risk reduction]]></category>
		<category><![CDATA[chronic disease management]]></category>
		<category><![CDATA[Community health interventions]]></category>
		<category><![CDATA[community-driven healthcare models]]></category>
		<category><![CDATA[patient empowerment]]></category>
		<category><![CDATA[patient empowerment in weight loss]]></category>
		<category><![CDATA[peer support networks]]></category>
		<category><![CDATA[peer-supported lifestyle interventions]]></category>
		<category><![CDATA[sustainable weight loss strategies]]></category>
		<category><![CDATA[weight loss maintenance]]></category>
		<guid isPermaLink="false">https://bioengineer.org/empowering-patients-with-continuous-care-to-sustain-weight-loss/</guid>

					<description><![CDATA[In a groundbreaking trial published in JAMA Internal Medicine, researchers have unveiled a novel approach to weight loss maintenance that significantly outperforms traditional professional treatments by leveraging patient-delivered lifestyle interventions enhanced with peer support. This innovative method involves mentor interventionists who operate alongside peers, creating a dynamic support system that empowers patients to sustain healthier [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">246865</post-id>	</item>
		<item>
		<title>Oral Semaglutide Significantly Decreases Incidence of Heart Attacks and Strokes in Type 2 Diabetes Patients</title>
		<link>https://bioengineer.org/oral-semaglutide-significantly-decreases-incidence-of-heart-attacks-and-strokes-in-type-2-diabetes-patients/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sat, 29 Mar 2025 18:36:32 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[cardiovascular outcomes]]></category>
		<category><![CDATA[cardiovascular risk reduction]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[GLP-1 receptor agonist]]></category>
		<category><![CDATA[heart attack prevention]]></category>
		<category><![CDATA[oral semaglutide]]></category>
		<category><![CDATA[stroke prevention]]></category>
		<category><![CDATA[Type 2 diabetes]]></category>
		<guid isPermaLink="false">https://bioengineer.org/oral-semaglutide-significantly-decreases-incidence-of-heart-attacks-and-strokes-in-type-2-diabetes-patients/</guid>

					<description><![CDATA[In recent years, the therapeutic landscape for type 2 diabetes has witnessed groundbreaking advancements, particularly with the introduction of medications like semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. This drug has gained significant attention for its remarkable efficacy not just in managing blood sugar levels but also in addressing weight gain and even alcohol cravings. [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">239539</post-id>	</item>
	</channel>
</rss>
